Luteinizing hormone releasing hormone(Johnson & Johnson)(Luteinizing hormone releasing hormone(Johnson & Johnson))

概要

基本信息

药物类型

激素

别名-

靶点

GnRHR

作用方式

激动剂

作用机制

GnRHR激动剂(促性腺激素释放激素受体激动剂)

治疗领域

泌尿生殖系统疾病

在研适应症-

非在研适应症

女性不孕症

原研机构

Johnson & Johnson

在研机构-

非在研机构

Johnson & Johnson

权益机构-

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Luteinizing hormone releasing hormone(Johnson & Johnson) 相关的临床试验

NCT04964934

/ Active, not recruiting临床3期

A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole)+ CDK4/6 Inhibitor in HR+/HER2-MBC Patients With Detectable ESR1Mutation Without Disease Progression During 1L Treatment With Aromatase Inhibitor+ CDK4/6 Inhibitor- A ctDNA Guided Early Switch Study

The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.

开始日期2021-06-30

申办/合作机构

AstraZeneca PLC

JPRN-UMIN000009079

/ RecruitingN/AIIT

The effect of luteinizing hormone-releasing hormone antagonist in the progression prostate cancer with initial luteinizing hormone-releasing hormone agonist - PC-antagonist

开始日期2012-11-01

申办/合作机构-

ACTRN12607000082404

/ Not yet recruiting临床2期IIT

A pilot study to evaluate the feasibility, safety and tolerability of neoadjuvant triple therapy with zoledronic acid, docetaxel, and luteinising hormone-releasing hormone (LH-RH) analogue for men with high-risk prostate cancer to be treated by radical prostatectomy

开始日期2007-04-01

申办/合作机构-

100 项与 Luteinizing hormone releasing hormone(Johnson & Johnson) 相关的临床结果

登录后查看更多信息

100 项与 Luteinizing hormone releasing hormone(Johnson & Johnson) 相关的转化医学

登录后查看更多信息

100 项与 Luteinizing hormone releasing hormone(Johnson & Johnson) 相关的专利（医药）

登录后查看更多信息

305

项与 Luteinizing hormone releasing hormone(Johnson & Johnson) 相关的文献（医药）

2025-03-01·Journal of Alzheimer’s Disease

Androgen deprivation therapy and dementia risk: An updated and dose-response meta-analysis

Review

作者: Teng, Yuou ; Tian, Jinzhou ; Zhu, Shun ; Shi, Jing ; Ni, Jingnian ; Long, Siwei ; Yao, Yirou

BackgroundThe association between androgen deprivation therapy (ADT) and dementia risk is controversial, and the dose-response relationship between them remains unclear.ObjectiveWe aim to further clarify the relationship between ADT and dementia risk.MethodsPubMed, Web of Science, Embase, and Cochrane Library databases were systematically searched up to September 2024 to identify relevant studies. A meta-analysis was conducted using hazard ratios (HR) and 95% confidence intervals (CI) as pooled indicators. The robust error meta-regression (REMR) approach was performed to explore the dose-response relationship. Heterogeneity was assessed using I² statistics, and subgroup analysis, sensitivity analysis, and meta-regressions were conducted. Publication bias was evaluated with a funnel plot and Egger's test.ResultsOur meta-analysis of 21 studies involving 2,278,835 patients revealed that ADT significantly increased the risk of overall dementia (HR = 1.14, 95% CI: 1.06–1.20) and Alzheimer's disease (AD) (HR = 1.15, 95% CI: 1.06–1.23), but not non-AD dementia (HR = 1.01, 95% CI: 0.89–1.16). For ADT subtypes, anti-androgens increased the risk of overall dementia (HR = 1.27, 95% CI: 1.09–1.49), particularly for AD (HR = 1.53, 95% CI: 1.19–1.97), while Luteinizing hormone-releasing hormone therapy and bilateral orchiectomy were not linked to the risk of any dementia subtype. A bell-shaped non-linear relationship between ADT duration and dementia risk was observed, with the highest risk observed at 15.5 to 21.5 months (HR = 1.25), which was confirmed by subgroup analysis for AD.ConclusionsThe risk of overall dementia and AD were found to be significantly associated with ADT in a bell-shaped dose-response effect.

2024-06-19·Cureus

Ureteral Metastasis From Prostate Cancer: A Report of Two Cases

Article

作者: McGee, Matthew D ; Contractor, Renish N ; Simhadri, Prathap ; Gerhold, Cameron ; Fynes, Evan

Prostate adenocarcinoma (PCa) is the second most common cause of cancer in men, but metastases to the ureter are exceedingly rare. Here, we present two cases with differing clinical symptoms and treatment courses but ultimately the same diagnosis. The two cases presented here had differing clinical presentations: one with lower urinary tract symptoms and the other with hydronephrosis. Systemic therapy with a luteinizing hormone-releasing hormone (LHrH) agonist appears to help with clinical outcomes in both cases reported here. Although such cases are extremely rare, consideration as a differential and early detection can impact a patient's clinical outcomes. For patients with PCa that present with obstructive urinary symptoms, there may be a clinical benefit to perform a thorough metastatic work-up for seeding to other parts of the urinary tract.

2024-02-16·Clinical Cancer Research

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Article

作者: Bardia, Aditya ; Kabos, Peter ; Bond, John W. ; Neilan, Tomas G. ; López-Miranda, Elena ; Gates, Mary R. ; Fredrickson, Jill ; Turner, Nicholas C. ; Moore, Heather M. ; García-Estévez, Laura ; Sohn, Joohyuk ; Villanueva-Vázquez, Rafael ; Lim, Elgene ; Bellet, Meritxell ; Loi, Sherene ; Chang, Ching-Wei ; Pérez-García, Jose M. ; Jhaveri, Komal L. ; Eng-Wong, Jennifer ; Pérez-Fidalgo, J. Alejandro ; Boni, Valentina ; Yu, Jiajie

AbstractPurpose:Giredestrant is an investigational next-generation, oral, selective estrogen receptor antagonist and degrader for the treatment of estrogen receptor–positive (ER+) breast cancer. We present the primary analysis results of the phase Ia/b GO39932 study (NCT03332797).Patients and Methods:Patients with ER+, HER2-negative locally advanced/metastatic breast cancer previously treated with endocrine therapy received single-agent giredestrant (10, 30, 90, or 250 mg), or giredestrant (100 mg) ± palbociclib 125 mg ± luteinizing hormone-releasing hormone (LHRH) agonist. Detailed cardiovascular assessment was conducted with giredestrant 100 mg. Endpoints included safety (primary), pharmacokinetics, pharmacodynamics, and efficacy.Results:As of January 28, 2021, with 175 patients enrolled, no dose-limiting toxicity was observed, and the MTD was not reached. Adverse events (AE) related to giredestrant occurred in 64.9% and 59.4% of patients in the single-agent ± LHRH agonist and giredestrant + palbociclib ± LHRH agonist cohorts, respectively (giredestrant-only–related grade 3/4 AEs were reported in 4.5% of patients across the single-agent cohorts and 3.1% of those with giredestrant + palbociclib). Dose-dependent asymptomatic bradycardia was observed, but no clinically significant changes in cardiac-related outcomes: heart rate, blood pressure, or exercise duration. Clinical benefit was observed in all cohorts (48.6% of patients in the single-agent cohort and 81.3% in the giredestrant + palbociclib ± LHRH agonist cohort), with no clear dose relationship, including in patients with ESR1-mutated tumors.Conclusions:Giredestrant was well tolerated and clinically active in patients who progressed on prior endocrine therapy. Results warrant further evaluation of giredestrant in randomized trials in early- and late-stage ER+ breast cancer.

100 项与 Luteinizing hormone releasing hormone(Johnson & Johnson) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
女性不孕症	临床1期	-	Johnson & Johnson	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO_GU2020	N/A	前列腺癌	-	Luteinizing hormone-releasing hormone agonists (LHRH) (Late dosing of LHRH agonists)	淵鬱簾築築簾製構簾艱(積糧鏇醖壓憲憲顧製夢) = 醖餘獵衊淵鬱顧衊廠夢遞鏇簾繭膚蓋鏇觸憲選 (繭積獵網壓範廠壓齋衊 ) 更多	-	2020-02-19
				Luteinizing hormone-releasing hormone agonists (LHRH) (Early/on-time dosing of LHRH agonists)	遞鑰觸積醖壓艱窪襯築(鑰廠積糧鹹鬱醖膚簾構) = 製積衊憲獵鏇憲獵顧網齋夢膚簾網憲範齋網蓋 (範觸廠鹹簾糧觸鏇鏇顧 )